ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
Dow Jones
39.872,99
0,17%
Euro vs US Dollar
1,08573
-0,03%
Bitcoin
70.152,79
-1,81%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Axovant Gene Therapies Ltd (AXGT)

  7. Axovant Gene Therapies Ltd (AXGT) News

AXGT

Axovant Gene Therapies (AXGT)

Axovant Gene Therapies Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:AXGT
DatumZeitQuelleÜberschriftSymbolFirma
25/04/202322h05Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/04/202322h17Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/04/202322h14Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AXGTAxovant Gene Therapies Ltd
12/04/202314h52Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/04/202322h08Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/04/202322h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/03/202311h03Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
15/03/202321h26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
21/02/202322h06Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/02/202313h04Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/02/202313h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/02/202312h47Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AXGTAxovant Gene Therapies Ltd
13/02/202314h53Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/02/202322h01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:AXGTAxovant Gene Therapies Ltd
09/02/202312h01Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/12/202222h11Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/12/202222h05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/11/202213h04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/11/202213h03Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/09/202222h09Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
11/08/202213h04Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/06/202213h02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/02/202219h58Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
11/02/202213h03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
11/02/202213h01Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/02/202223h08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AXGTAxovant Gene Therapies Ltd
09/02/202213h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
25/01/202222h51Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/12/202100h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/12/202100h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AXGTAxovant Gene Therapies Ltd
 Showing the most relevant articles for your search:NASDAQ:AXGT

Kürzlich von Ihnen besucht

TG
TUI1
Tui
DBI
SDXP
SDAX
TG
BAS
BASF
NASDAQ
MSFT
Microsoft
COIN
SOLUSD
Solana
TG
BAYN
Bayer
USOTC
RHHBY
Roche (QX)
NYSE
NKE
Nike
NASDAQ
AAPL
Apple
NYSE
MCD
McDonalds
USOTC
BNPQY
BNP Paribas (QX)
TG
LHA
Deutsche Lufthansa
COIN
ETHUSD
Ethereum
DBI
DAX
DAX
NYSE
JPM
JP Morgan Chase
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten